Pier Francesco Ferrucci1, Marko Lens2, Emilia Cocorocchio3. 1. Tumor Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. pier.ferrucci@ieo.it. 2. King's College, London, UK. 3. Department of Hemato-Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Abstract
PURPOSE OF REVIEW: To review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma. RECENT FINDINGS: Programmed death-1 pathway inhibitors administered with BRAF/MEK inhibitors showed promising anti-tumour activity in BRAF-mutated advanced melanoma and were investigated for safety and efficacy in three large international clinical trials. Although, in two out of those three randomized phase III studies, progression-free survival (PFS) did not reach statistical significance, results showed that duration of response (DOR) and overall survival (OS) were improved using combined therapy, sustaining the scientific rationale for its use at least in a subset of metastatic melanomas. However, the frequent occurrence of autoimmunity-induced toxicities should be considered since it is limiting the continuity and the wide application of these regimens. Novel treatment modalities combining targeted therapy with checkpoint inhibitors require further clinical investigation and elucidation of their effect on the immune system and cancer cell modulation.
PURPOSE OF REVIEW: To review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma. RECENT FINDINGS: Programmed death-1 pathway inhibitors administered with BRAF/MEK inhibitors showed promising anti-tumour activity in BRAF-mutated advanced melanoma and were investigated for safety and efficacy in three large international clinical trials. Although, in two out of those three randomized phase III studies, progression-free survival (PFS) did not reach statistical significance, results showed that duration of response (DOR) and overall survival (OS) were improved using combined therapy, sustaining the scientific rationale for its use at least in a subset of metastatic melanomas. However, the frequent occurrence of autoimmunity-induced toxicities should be considered since it is limiting the continuity and the wide application of these regimens. Novel treatment modalities combining targeted therapy with checkpoint inhibitors require further clinical investigation and elucidation of their effect on the immune system and cancer cell modulation.
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245
Authors: James Larkin; Paolo A Ascierto; Brigitte Dréno; Victoria Atkinson; Gabriella Liszkay; Michele Maio; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Mika A Sovak; Ilsung Chang; Nicholas Choong; Stephen P Hack; Grant A McArthur; Antoni Ribas Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245
Authors: Dirk Schadendorf; Georgina V Long; Daniil Stroiakovski; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion-Sileni; Jacob Schachter; Claus Garbe; Caroline Dutriaux; Helen Gogas; Mario Mandalà; John B A G Haanen; Céleste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Jean-Jacques Grob; Paul Nathan; Antoni Ribas; Michael A Davies; Ying Zhang; Mathilde Kaper; Bijoyesh Mookerjee; Jeffrey J Legos; Keith T Flaherty; Caroline Robert Journal: Eur J Cancer Date: 2017-06-22 Impact factor: 9.162
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean-Jacques Grob; Vanna Chiarion-Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Suzanne Swann; Jeffrey J Legos; Fan Jin; Bijoyesh Mookerjee; Keith Flaherty Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: Caroline Robert; Antoni Ribas; Jacob Schachter; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona M McNeil; Michal Lotem; James M G Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Teresa M Petrella; Omid Hamid; Shu-Chih Su; Clemens Krepler; Nageatte Ibrahim; Georgina V Long Journal: Lancet Oncol Date: 2019-07-22 Impact factor: 41.316
Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: Douglas B Johnson; Keith T Flaherty; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Richard F Kefford; Omid Hamid; Lynn Schuchter; Jonathan Cebon; William H Sharfman; Robert R McWilliams; Mario Sznol; Donald P Lawrence; Geoffrey T Gibney; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Kiran Patel; Nageatte Ibrahim; Peng Sun; Shonda Little; Elizabeth Cunningham; Jeffrey A Sosman; Adil Daud; Rene Gonzalez Journal: J Clin Oncol Date: 2014-10-06 Impact factor: 44.544
Authors: Karl D Lewis; James Larkin; Antoni Ribas; Keith T Flaherty; Grant A McArthur; Paolo A Ascierto; Brigitte Dréno; Yibing Yan; Matthew Wongchenko; Edward McKenna; Qian Zhu; Yong Mun; Axel Hauschild Journal: Br J Cancer Date: 2019-08-16 Impact factor: 7.640
Authors: Paweł Rogala; Anna M Czarnecka; Bożena Cybulska-Stopa; Krzysztof Ostaszewski; Karolina Piejko; Marcin Ziętek; Robert Dziura; Ewa Rutkowska; Łukasz Galus; Natasza Kempa-Kamińska; Jacek Calik; Agata Sałek-Zań; Tomasz Zemełka; Wiesław Bal; Agnieszka Kamycka; Tomasz Świtaj; Grażyna Kamińska-Winciorek; Rafał Suwiński; Jacek Mackiewicz; Piotr Rutkowski Journal: J Clin Med Date: 2022-04-17 Impact factor: 4.964